Enantiomeric separation and quantitation of warfarin and its metabolites in human plasma by LC-MS/MS by Mostafa, Ahmed Abd-Alazim
European	Journal	of	Chemistry	7	(3)	(2016)	357‐362	
	
European	Journal	of	Chemistry	
ISSN	2153‐2249	(Print)	/	ISSN	2153‐2257	(Online)		2016	Atlanta	Publishing	House	LLC	‐	All	rights	reserved	‐	Printed	in	the	USA	
http://dx.doi.org/10.5155/eurjchem.7.3.357-362.1470 
	
	
	
	
European	Journal	of	Chemistry	
Journal	webpage:	www.eurjchem.com	 	
	 	 	
Enantiomeric	separation	and	quantitation	of	warfarin	and	its	metabolites	in	
human	plasma	by	LC‐MS/MS	
Ahmed	Abd‐Alazim	Mostafa	1,2,*	
1	Pharmaceutical	Chemistry	Department,	Faculty	of	Pharmacy,	Helwan	University,	Egypt,	Ein	Helwan,	11795,	Cairo,	Egypt	
2	Therapeutics	Research	Centre,	School	of	Medicine,	The	University	of	Queensland,	Princess	Alexandra	Hospital,	Woolloongabba,	QLD,	4102,	Australia	
*	Corresponding	author	at:	Pharmaceutical	Chemistry	Department,	Faculty	of	Pharmacy,	Helwan	University,	Egypt,	Ein	Helwan,	11795,	Cairo,	Egypt.		
Tel.:	+202.3.7836552.	Fax:	+202.2.5541601.	E‐mail	address:	ahmead34@yahoo.com	(A.A.	Mostafa).	
	
	
	 	
	 	 	
ARTICLE	INFORMATION	 	 ABSTRACT	
	
DOI: 10.5155/eurjchem.7.3.357-362.1470	
Received:	18	June	2016	
Received	in	revised	form:	12	July	2016	
Accepted:	14	July	2016	
Published	online:	30	September	2016	
Printed:	30	September	2016
 
	 The	 enantiomeric	 separation	 of	 warfarin	 (WAR)	 enantiomers	 and	 its	 hydroxy	metabolites
positional	 isomers	 is	 described	 in	 this	 work.	 The	 utilization	 of	 chiral	 chromatography
coupled	 to	 Tandem	mass	 spectrometry	 helps	 to	 achieve	 that.	 The	 developed	method	was
able	to	separate	R,S‐warfarin	and	enantiomers	of	4,7,10‐hydroxy	warfarin	in	human	plasma.
Plasma	 samples	 were	 processed	 with	 simple	 protein	 precipitation	 with	 acetonitrile.	 The
chromatographic	 separation	was	 done	 on	 chiral	 Astec	 Chirobiotic	 V	 column	with	 gradient
flow	of	0.1%	aqueous	formic	acid	and	0.1%	formic	in	acetonitrile:water	(95:5,	v:v).	The	mass
spectroscopic	detection	was	done	via	negative	mode	multiple	reaction	monitoring	(MRM)	on
a	 triple	quadrupole	mass	spectrometer	coupled	with	positive	electrospray	 ionization	(ESI).
Linearity	 of	 the	 method	 was	 valid	 over	 a	 concentration	 range	 of	 125.00‐0.13	µg/mL	 for
racemic	WAR,	47.000‐0.088	µg/mL	for	racemic	4’‐OH‐WAR,	56.00‐0.18	µg/mL	for	racemic	7‐
OH‐WAR	and	56.00‐0.02	µg/mL	for	racemic	10‐OH‐WAR.	The	LLOQs	were	found	to	be	0.13
µg/mL	 for	 racemic	WAR,	0.088	µg/mL	 for	 racemic	4’‐OH‐WAR,	 0.18	µg/mL	 for	 racemic	7‐
OH‐WAR	 and	 0.02	 µg/mL	 for	 racemic	 10‐OH‐WAR.	 The	 method	 was	 validated	 for	 matrix
effect,	 intra‐	 and	 inter‐day	 precision,	 freeze/thaw	 and	 storage	 stability.	 Accuracy	 and
precision	 were	 within	 acceptable	 range	 (<15%).	 Enantiomeric	 forms	 of	 WAR	 and	 its
metabolites	 were	 separated	 by	 the	 chiral	 column.	 Standards	 for	 R‐	 and	 S‐WAR	 identified
peak	2	as	S‐WAR	while	metabolite	peaks	could	not	be	definitively	identified.	Peak	2	for	7‐OH‐
WAR	gave	higher	blood	levels,	while	the	opposite	applied	to	10‐OH‐WAR.	
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1.	Introduction	
	
Warfarin	 (4‐hydroxy‐3‐(3‐oxo‐1‐phenylbutyl)chromen‐2‐
one)	 is	 one	 of	 the	 most	 frequently	 prescribed	 anticoagulant	
(Figure	1).	 It	was	administrated	orally	 in	 the	form	of	racemic	
mixture	R‐	and	S‐WAR	as	treatment	and	prophylaxis	of	Venous	
Thromboembolism	 [1‐3].	 S‐WAR	 is	 3‐5	 times	 potent	 that	 R‐
enantiomer,	metabolised	by	P450	 (CYP)	2C9	 to	 form	 inactive	
S‐7‐hydroxy	metabolite	(7‐OH‐WAR)	[4,5].	Genetic	variation	in	
CYP2C9	 impact	 the	 clearance	 of	 S‐WAR	 with	 increasing	 the	
risk	 of	 bleeding	 during	 induction	 period	 of	 treatment	 [6‐8].	
The	 metabolism	 of	 WAR	 show	 a	 regioselectivity	 for	 the	
products,	 for	example	S‐WAR	is	metabolised	to	7‐OH‐WAR	as	
major	product,	however	4,6‐OH‐WAR	were	produced	as	minor	
product.	On	 the	other	hand,	R‐WAR	 is	metabolised	 to	4,6,7,8,	
10‐OH‐WAR,	 however	 6,10‐OH‐WAR	 are	 the	 major	 products	
[9,10].	WAR	 is	 widely	 used	 for	 treatment	 and	 prevention	 of	
thrombosis	 however,	 its	 uses	 always	 accompanied	 by	
bleeding.	
Due	to	its	narrow	therapeutic	index	and	genetic	metabolic	
variations	 it	 is	hard	 to	reach	a	safe	 therapeutic	action	[11],	 it	
was	strongly	recommended	to	monitor	WAR	level	in	blood	to	
insure	 that	 warfarin	 is	 working	 safely	 and	 effectively	 [12].	
Many	drugs	have	a	chiral	centre	in	their	structures,	producing	
enantiomers,	 having	 different	 potencies	 and	 activities	 [13].	
Because	of	enantiomers	have	the	same	physical	and	chemical	
properties;	 it	 cannot	 separate	 through	 achiral	 stationary	
phase.	 Chiral	 stationary	 phase	 plays	 an	 important	 role	 in	
enantiomers	 separation	 by	 chromatography	 [14].	 The	 differ‐
rence	 in	 potency	 between	 R,S‐WAR	 has	 results	 stress	 to	
develop	 a	 sensitive,	 robust	 and	 selective	method	 for	 separa‐
tion	and	analysis	of	enantiomers	of	WAR	and	its	metabolites	in	
plasma.	 This	 obviously	 will	 facilitate	 drug	 monitoring	 and	
saving	 time	 and	 simplify	 the	 producers	 of	 urine	 sample	
collection	 [15].	 There	 are	many	HPLC	methods	 coupled	with	
UV,	fluorescence	and	mass	detectors	used	for	analysis	of	WAR	
and	or	its	metabolites.	Although	some	of	them	used	for	chiral	
separation	 of	 warfarin	 and	 hydroxylated	 metabolites,	 they	
used	 non‐specific	 detectors	 as	 UV	 and	 florescence	 [16‐18].	
Reported	 LC/MS	 methods	 for	 WAR	 were	 use	 either	 achiral	
separation	or	chiral	separation	with	only	limited	consideration	
of	 metabolites	 [3,15,19].	 The	 novelty	 of	 my	 method	 comes	
from	it	used	for	separation	of	enantiomers	of	WAR	and	three	
of	its	metabolites.	
The	 main	 aim	 in	 this	 study	 is	 to	 develop	 and	 validate	 a	
simple	and	rapid	method	for	the	simultaneous	quantitation	of	
enantiomers	of	WAR	and	its	metabolites	in	clinical	samples.	
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Figure	1.	Chemical	structures	of	the	analytes:	Warfarin	(WAR),	4‐hydroxy	warfarin	(4’‐OH‐WAR),	7‐hydroxy	warfarin	(7‐OH‐WAR),	10‐hydroxy	warfarin	(10‐
OH‐WAR).	
	
	
2.	Experimental	
	
2.1.	Materials	and	standards	
	
Warfarin,	 4‐hydroxy	 warfarin	 (4’‐OH‐WAR),	 7‐hydroxy	
warfarin	 (7‐OH‐WAR),	 10‐hydroxy	 warfarin	 (10‐OH‐WAR)	
and	 4‐hydroxy	nitro	phenol	 (IS)	were	purchased	 from	 Sigma	
(Germany).	All	 solvents	were	HPLC	grade	 and	were	obtained	
from	 Merck	 (Kilsyth,	 Australia).	 Blank	 human	 plasma	 was	
kindly	donated	by	the	Australian	Red	Cross.	
	
2.2.	Equipment	
	
The	 analysis	was	 performed	 using	 an	 API	 2000	 (Applied	
Biosystems/MDS	Analytical	Technologies	Inc.,	Foster	City,	CA,	
USA)	 triple	 quadrupole	mass	 spectrometer	 equipped	with	 an	
electrospray	ionization	(ESI)	source	and	a	Valco	diverter	valve.	
The	HPLC	system	consisted	of	a	Shimadzu	SLC‐10A	VP	system	
controller	 with	 three	 LC‐10AD	 pumps	 and	 a	 SIL‐20AC‐HT	
autosampler	operated	at	4	°C.	
	
2.3.	Chromatographic	and	mass	spectrometric	conditions	
	
Chromatographic	 separation	 was	 performed	 on	 a	 chiral	
Astec	ChirobioticV	column	(100	×	4.6	mm,	5	µm	particle	size)	
with	an	Astec	Cyclobond	I	guard	column	(20	×	4.0	mm,	5	µm).	
Gradient	 flow	of	a	5:95	mixture	of	0.1%	aqueous	 formic	acid	
and	 acetonitrile	 elutes	 the	 analytes	 with	 good	 chromate‐
graphic	 separation.	 The	 negative‐ion	 mass	 spectrometric	
detection	 method	 utilised	 electrospray	 ionization	 and	 the	
multiple	 reaction	 monitoring	 (MRM)	mode.	 Optimisations	 of	
mass	spectrometric	conditions	were	done	for	each	compound	
by	 continuously	 infusing	 a	 standard	 solution	 (1	 µg/mL	 in	
mobile	phase)	at	10	µL/min.	The	optimized	parameters	were	
as	 follows:	 turbo	 ion	 spray	 temperature,	 400	 °C;	 ion	 spray	
voltage,	5000	V;	declustering	potential	(DP),	‐60	V	(WAR),	‐65	
V	 (4’‐OH‐WAR),	 ‐40	 V	 (7‐OH‐WAR),	 ‐50	 V	 (10‐OH‐WAR)	 and					
‐46	V	4‐nitro	phenol	(IS);	entrance	potential	(EP),	‐9	V	(WAR),	
‐9V	 (4‐OH‐WAR),	 ‐8	 V	 (7‐OH‐WAR),	 ‐5	 V	 (10‐OH‐WAR)	 and						
‐12	 V	 (IS);	 collision	 energy	 (CE),	 ‐25	 V	 (WAR),	 ‐30	 V4’‐OH‐
WAR,	‐30	V	(7‐OH‐WAR),	 ‐30	V	(10‐OH‐WAR)	and	‐25	V	(IS);	
collision	cell	entrance	potential	(CEP),	‐16.2	V	(WAR),	‐16	V	(4‐
OH‐WAR),	 ‐16.6	 V	 (7‐OH‐WAR),	 ‐16.6	 V	 (10‐OH‐WAR)	 and								
‐20.41	V	(IS);	 collision	cell	 exit	potential	 (CXP),	 ‐14	V	(WAR),					
‐10	 V	 (4‐OH‐WAR),	 ‐10	 V	 (7‐OH‐WAR),	 ‐10	 V	 (10‐OH‐WAR)	
and	‐10	V	(IS).	The	MRM	ion	transition	were	307	→	161.1	for	
WAR,	323	→	161.1	for	4’‐OH‐WAR,	323	→	177	for	7‐OH‐WAR,	
323	→	250	for	10‐OH‐WAR	and	137.9	→	107	for	(IS).	Applied	
Biosystems	Analyst	version	1.4.2	software	was	used	to	control	
the	LC‐MS/MS	system,	collect	and	analyse	the	data.	
	
2.4.	Preparation	of	stock	and	working	solutions	
	
Four	 250	µg/mL	 stock	 solutions	 of	 each	 analyte	WAR,	 4‐
OH‐WAR,	 7‐OH‐WAR	 and	 10‐OH‐WAR	 were	 prepared	 by	
dissolving	each	compound	in	phosphate	buffer	(100	mM,	pH	=	
7.4).	 These	 were	 mixed	 with	 buffer	 to	 produce	 a	 combined	
stock	at	125	µg/mL	for	WAR,	47	for	4’‐OH‐WAR,	and	56	µg/mL	
for	 7‐OH‐WAR	 and	 10‐OH‐WAR.	 Quality	 control	 stock	
solutions	 at	 the	 same	 concentrations	 were	 prepared	
independently.	
A	 125	µg/mL	 stock	 solution	 of	 IS	 was	 prepared	 in	
methanol.	 The	 working	 solution	 of	 IS	 then	 was	 prepared	 by	
diluting	 an	 aliquot	 of	 stock	 solution	 with	 phosphate	 buffer	
(100	 mM,	 pH	 =	 7.4)	 to	 achieve	 the	 concentration	 of	
62.5	ng/mL.	All	 stock	solutions	were	kept	at	 ‐20	°C	until	use,	
whilst	the	working	solutions	were	kept	at	4	°C	and	discarded	
within	30	days.		
	
2.5.	Preparation	of	calibration	standards	and	quality	
control	(QC)	samples	
	
An	 upper	 limit	 of	 quantification	 (ULOQ)	 calibration	
standard	 was	 prepared	 by	 spiking	 the	 combined	 standard	
stock	 into	 pre‐screen	 human	plasma	 to	 125	µg/mL	 for	WAR,	
47	 µg/mL	 for	 4’‐OH‐WAR,	 and	 56	µg/mL	 for	 7‐OH‐WAR	 and	
10‐OH‐WAR.	 Eight	 further	 calibration	 standards	 were	
prepared	 by	 serial	 dilution	 with	 plasma	 to	 obtain	 concent‐
ration	 ranges	 of	 125‐0.13	µg/mL	 for	 WAR,	 47.000‐0.089	
µg/mL	 for	4’‐OH‐WAR,	56.00‐0.18	µg/mL	 for	7‐OH‐WAR	and	
56.00‐0.02	 µg/mL	 for	 10‐OH‐WAR.	 Since	 the	 supplied	
standard	 are	 racemic	 the	 above	 standards	 concentration	 are	
divided	 by	 two	 to	 obtain	 the	 concentrations	 of	 each	
enantiomer.		
Quality	 control	 samples	 were	 prepared	 by	 spiking	 blank	
plasma	with	the	quality	control	stock	solution	to	concentration	
of	100,	50	and	1	µg/mL	for	WAR	and	40,	20	and	0.3	µg/mL	for	
the	 other	 analytes.	 The	 calibration	 standards	 and	 quality	
control	samples	were	stored	at	‐70	°C	before	use.	
	
2.6.	Sample	preparation	
	
An	aliquot	(50	µL)	of	plasma	to	be	tested	was	mixed	with	
50	 µL	 IS	 working	 solution	 and	 200	 µL	 of	 acetonitrile	 were	
added	 to	 promote	 protein	 precipitation.	 After	 vortex‐mixing	
for	10	s	and	centrifuging	at	1000	×	g	for	10	min,	approximately	
200	 µL	 of	 the	 supernatant	 was	 transferred	 into	 a	 HPLC	 vial	
and	5	µL	was	analysed	by	LCMS.	
	
2.7.	Method	validation	
	
2.7.1.	Selectivity	and	matrix	effect	
	
To	 determine	 whether	 variation	 in	 the	 composition	 of	
human	 plasma	 would	 be	 likely	 to	 cause	 ion	 suppression	 or	
other	 matrix	 effect	 on	 the	 measured	 analyte	 levels,	 five	
different	 lots	 of	 blank	 human	 plasma	 were	 spiked	 with	 all	
analytes	 at	 both	 high	 and	 low	 concentration	 and	 assayed	
against	a	calibration	set	prepared	in	a	sixth	lot	of	plasma.	The	
accuracy	(%	of	normal	concentration)	and	precision	(%R.S.D.)	
are	determined.	
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Table	1.	Matrix	effect	results	of	WAR	and	its	metabolites	(n	=	5).	
Analyte	 Nominal	concentration	(ng/mL)	 Matrix	effect	(%)	 %R.S.D.	
Racemic	WAR	 0.26	 96.2 8.10
62.50	 102.8 3.66
Racemic	4’‐OH‐WAR	 0.17	 110.5 6.70
23.00	 97.3 5.20
Racemic	7‐OH‐WAR	 0.36	 103.2	 10.00	
28.00	 103.8	 5.60	
Racemic	10‐OH‐WAR	 0.04	 104.2 9.20
28.00	 98.5 3.47
	
	
2.7.2.	Linearity	and	lower	limit	of	quantification	(LLOQ)	
	
The	stock	solutions	are	composed	of	racemic	mixture	from	
R,S‐WAR	 and	 metabolites.	 Enantiomers	 are	 equimolar	 in	
racemic	mixture.	The	linearity	of	the	method	was	determined	
by	 analysing	 eight	 calibration	 standard	 samples	 at	 concent‐
rations	 ranges	 of	 62.500‐0.065	µg/mL	 for	 enantiomers	 of	
WAR,	 23.500‐0.044	 µg/mL	 for	 enantiomers	 of	 4’‐OH‐WAR,	
28.00‐0.09	 µg/mL	 for	 enantiomers	 of	 7‐OH‐WAR	 and	 28.00‐
0.01	 µg/mL	 for	 enantiomers	 of	 10‐OH‐WAR.	 The	 acceptable	
tolerance	 for	 accuracy	 and	 precision	was	 20%	 for	 LLOQ	 and	
15%	 for	 other	 standard	 points.	 The	 calibration	 curve	 was	
constructed	by	least	squares	quadratic	regression	of	the	peak	
area	 ratios	 of	 each	 analyte	 to	 IS	 obtained	 against	 the	
corresponding	 concentrations	 using	 a	 weighting	 factor	 of	
1/[Concentration]2.	 The	 LLOQ	 was	 defined	 as	 the	 lowest	
concentration	 in	 the	 calibration	 curve	 with	 acceptable	
precision	and	accuracy.	
	
2.7.3.	Accuracy	and	precision		
	
The	 intra‐day	 accuracy	 and	 precision	 were	 evaluated	 by	
analysing	 five	 replicates	 of	 quality	 controls	 (QCs)	 at	 three	
concentration	levels	in	a	single	batch	using	a	freshly	prepared	
calibration	 curve.	 Additional	 QC	 samples	were	 also	 analysed	
on	five	different	days	in	order	to	assess	inter‐day	accuracy	and	
precision.	 Precision	 was	 represented	 by	 percent	 relative	
standard	 deviations	 (%R.S.D.)	 while	 the	 accuracy	 was	
percentage	of	the	calculated	concentration.	
	
2.7.4.	Stability	test	
	
The	 post‐preparative	 stability	 was	 determined	 by	
comparing	 the	 level	 found	 in	 freshly	 prepared	 samples	 to	
processed	samples	after	24	h	in	the	autosampler	at	4	°C.	Short‐
term	 stability	 in	 plasma	 for	 3	 h	 (bench	 storage)	 was	
determined	 at	 ambient	 temperature	 (24±3	 °C)	 at	 concent‐
rations	of	QC	samples.	The	stability	was	also	tested	after	three	
freeze/thaw	 cycles	 using	 QC	 samples	 of	 three	 different	
concentration	 levels.	 The	 samples	 were	 stored	 at	 ‐80	 °C	
between	 freeze/thaw	 cycles,	 and	 then	 they	 were	 thawed	 by	
allowing	 them	 to	 stand	 at	 room	 temperature	 for	
approximately	30	min.	The	samples	were	then	returned	to	the	
‐80	°C	freezer	for	24	h.		
	
3.	Results	and	discussion	
	
3.1.	LC‐MS/MS	optimization	and	sample	preparation	
	
During	 the	development	of	 the	method,	using	of	different	
achiral	columns	was	not	able	to	separate	enantiomers,	because	
it	 has	 the	 same	 physical	 and	 chemical	 properties	 especially	
same	retention	 time.	Using	of	chiral	 column,	 in	which	achiral	
silica	gel	(SiO2)	is	converted	into	a	chiral	stationary	phase	by	a	
reaction	 with	 a	 chiral	 molecule	 to	 form	 active	 chiral	 centre.	
Each	 enantiomer	 will	 bind	 to	 active	 chiral	 centre	 unequally	
and	 separation	will	 be	 occurred.	 Astec	 Chirobiotic	 V	 column	
was	used;	it	has	active	site	with	Vancomycin	which	contains	18	
chiral	 centres	 surrounding	 three	 pockets	 or	 cavities.	 These	
allow	 good	 separation	 and	 resolution	 of	 enantiomers.	 In	
comparison	to	other	published	method,	the	retention	times	of	
WAR	and	metabolites	were	short	[19].	
Different	chromatographic	conditions	were	investigated	to	
optimize	 sensitivity,	 peak	 shape	 and	 separation.	 The	 use	 of	
water	acetonitrile	and	formic	acid	as	mobile	phase	was	found	
to	be	preferable	for	analyte	separation	and	ionization	than	the	
use	of	ammonium	acetate.		
Based	 on	 the	 chemical	 structures	 of	 the	 analytes,	
electrospray	 ionization	 operated	 at	 negative	 ion	 mode	 was	
used	 for	 LC‐MS/MS	 analysis	 to	 provide	 optimum	 sensitivity	
and	selectivity.	Deprotonation	of	phenolic	OH	of	each	analyte	
([M‐H]‐.	 This	 form	was	 found	 to	 be	 dominant	 ions	 in	 the	Q1	
scan,	 and	 were	 used	 as	 the	 precursor	 ions	 to	 obtain	 Q3	
product	ion	spectra.	Multiple	reaction	monitoring	(MRM)	was	
used	 to	 decrease	 interference	 of	matrix	 components	 [20,21].	
The	MRM	 ion	 transition	were	 307	→	 161.1	 for	WAR,	 323	→	
161.1	 for	 4’‐OH‐WAR,	 323	→	177	 for	 7‐OH‐WAR,	 323	→	250	
for	10‐OH‐WAR	and	137.9	→	107	for	IS	in	Figure	2.	
	
3.2.	Method	validations	
	
3.2.1.	Selectivity	and	matrix	effect		
	
Six	different	lots	of	blank	human	plasma	were	checked	for	
any	 false	 positive	 MS	 responses.	 No	 interferences	 from	
endogenous	 plasma	 substances	 were	 observed	 and	 a	 good	
separation	 of	 the	 analytes	was	 achieved	 using	 the	 described	
LC‐MS/MS	conditions.	As	shown	in	Table	1,	no	obvious	matrix	
effects	were	 found	 for	 all	 the	 analytes	 as	 the	 results	 ranged	
from	96.2	to	110.5%	which	is	within	the	acceptable	limit.	
	
3.2.2.	Linearity	and	LLOQ	
	
Calibration	 curves	 in	 spiked	 human	 plasma	 were	 linear	
over	 the	 range	 of	 125.00‐0.13	µg/mL	 for	 racemic	 WAR,	
47.000‐0.088	 µg/mL	 for	 racemic	 4’‐OH‐WAR,	 56.00‐0.18	
µg/mL	 for	 racemic	 7‐OH‐WAR	 and	 56.00‐0.02	 µg/mL	 for	
racemic	10‐OH‐WAR.	The	linearity	of	standard	curves	(r2)	for	
all	 analytes	were	greater	 than	0.99	using	1/c2	weighting.	For	
each	 point	 of	 calibration	 standards,	 the	 back	 calculated	
concentrations	 from	 the	 equation	 of	 calibration	 curves	 were	
within	 ±15%	 deviation.	 The	 calibration	 curve	 had	 a	 reliable	
reproducibility	 across	 the	calibration	 range.	The	LLOQs	were	
found	 to	 be	 0.13	 µg/mL	 for	 racemic	WAR,	 0.088	 µg/mL	 for	
racemic	4’‐OH‐WAR	 ,	0.18	µg/mL	for	racemic	7‐OH‐WAR	and	
0.02	µg/mL	for	racemic	10‐OH‐WAR,	with	acceptable	accuracy	
98.1%	for	racemic	WAR,	96.7%	for	racemic	4’‐OH‐WAR,	98.9%	
for	 racemic	 7‐OH‐WAR	 and	 97.6%	 for	 racemic	 10‐OH‐WAR	
and	precision	1.70‐6.78%.	
	
3.2.3.	Accuracy	and	precision		
	
QC	 samples	 at	 three	 concentration	 levels	 (low,	 medium	
and	high)	with	five	replicates	at	each	level	were	processed	and	
analysed	 on	 the	 same	 day	 and	 also	 on	 five	 separate	 days	 to	
determine	intra‐	and	inter‐day	accuracy	and	precision	for	each	
analyte.	As	summarized	 in	Table	2,	 the	accuracy	ranged	from	
90.1‐106.5	 for	 racemic	 WAR,	 87.6‐98.5	 for	 racemic	 4’‐OH‐
WAR,	 93.2‐107.5	 for	 racemic	 7‐OH‐WAR	 and	 91.1‐107.4	 for	
racemic	10‐OH‐WAR	and	the	precision	was	within	11%	for	all	
analytes.		
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Table	2.	Intra‐	and	inter‐day	accuracy	(%	of	nominal	concentration)	and	precision	(%	RSD)	of	WAR	and	its	metabolites	in	human	plasma.	
Analyte	 Nominal	concentration	
(µg/mL)	
Intra‐day	(n=5)	 Inter‐day	(n=15)	
Accuracy	(%)	 Precision	(%) Accuracy	(%)	 Precision	(%)
Racemic		
WAR	
0.5	 99.2 10.04 100.8 6.94	
50	 103.1	 4.74	 105.9	 1.84	
100	 106.5 3.64 90.1 3.74	
Racemic		
4’‐OH‐WAR	
0.1	 91.2	 6.24	 93	 2.64	
20	 87.6 9.84 106 3.44	
40	 98.5 1.34 92.3 6.54	
Racemic		
7‐OH‐WAR	
0.2	 105.2 4.14 106.2 3.14	
22	 96.6 7.94 110.4 1.34	
50	 107.5	 1.74	 93.2	 2.94	
Racemic		
10‐OH‐WAR	
0.2	 97.7 2.64 98.2 3.24	
22	 91.1	 8.64	 107.4	 6.34	
50	 99.2 6.64 95.2 6.64	
	
	
	
	
	
	(a)	
	
	
	
(b)	
	
	
	
(c)	
	
	
	
(d)	
	
Figure	2.	Representative	extracted	ion	chromatogram	(XIC)	of	blank	plasma	and	calibration	standards	of	WAR	and	metabolites	at	lower	limit	of	quantification	
(LLOQ)	and	upper	limit	of	quantification	(ULOQ);	(a)	R‐WAR	and	S‐WAR	(b)	10‐OH‐WAR	(c)	4’‐OH_WAR	(d)	7‐OH‐WAR.	
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Table	3.	Stabilities	of	WAR	and	its	metabolites	in	human	plasma	QC	samples	(n=3).	
Analyte	 Nominal	concentration	
(µg	/	mL)	
%	Loss/gain	in	stability	study	
Post‐preparative Freeze‐thaw	 Short	term
Racemic	WAR	 50	 +3.44	% +5.82	%	 ‐2.5	%	
Racemic	4’‐OH‐WAR	 20	 +1.33% +8.53% ‐2.33%
Racemic	7‐OH‐WAR	 22	 ‐1.56	% +2.60	% +1.45	%
Racemic	10‐OH‐WAR	 22	 +4.15% +3.16	% +3.10%
	
	
	
	
	 	
	
Figure	3.	Plasma	concentration	versus	time	profiles	of	enantiomer	of	warfarin	and	3	of	its	metabolites.	
	
3.2.4.	Stability	
	
As	shown	in	Table	3,	buffered	plasma	samples	containing	
racemic	 WAR,	 racemic	 4’‐OH‐WAR,	 racemic	 7‐OH‐WAR	 and	
racemic	 10‐OH‐WAR	 were	 stable	 for	 up	 to	 3	 h	 at	 room	
temperature	 and	 for	 at	 least	 three	 freeze/thaw	 cycles.	 The	
prepared	 samples	 were	 stable	 for	 24	 h	 in	 the	 cooled	 auto‐
sampler.	 The	 relative	 deviations	 were	 within	 ±15%	 for	 all	
analytes	at	the	different	conditions	studied.	
	
3.3.	Application	to	clinical	study	
	
This	 method	 was	 applied	 to	 morning	 the	 metabolites	 of	
WAR	in	plasma	of	patient	under	treatment	enantiomeric	forms	
of	 WAR	 and	 its	 metabolites	 were	 separated	 by	 the	 chiral	
column.	 Standards	 for	R‐	 and	 S‐WAR	 identified	 peak	 2	 as	 S‐
WAR	 while	 metabolite	 peaks	 could	 not	 be	 definitively	
identified.	 Peak	 2	 for	 7‐OH‐WAR	 gave	 higher	 blood	 levels,	
while	the	opposite	applied	to	10‐OH‐WAR,	Figure	3.		
The	1st	and	2nd	eluted	peaks	of	WAR	and	metabolites	were	
identified	as	the	R‐	and	S‐	enantiomers,	respectively,	based	on	
known	 human	 metabolic	 pathways	 for	 WAR	 [22].	 R‐10‐OH‐
warfarin	 is	 the	 major	 metabolite	 in	 clinical	 samples	 from	
patients	 undergoing	 warfarin	 therapy,	 via	 the	 CYP3A4	
pathway	 (Peak	 1	 was	 the	 dominant	 peak).	 Hydroxylation	 at	
the	 7‐	 position	 is	 catalysed	 by	 CYP2C19	 and	 CYP2C9,	 but	
CYP2C9	predominates	with	an	almost	1000‐fold	higher	affinity	
for	 S‐WAR	 than	 R‐WAR	 (Peak	 2	 was	 the	 dominant	 peak).	
Identification	of	the	two	4’‐OH‐WAR	peaks	is	less	clear‐cut,	as	
multiple	 enzymes	 (e.g.	 CYP2C8	 and	 CYP3A4)	 are	 likely	 to	
contribute	 to	 this	 enzymatic	 pathway.	 In	 comparison	 to	
previous	methods	our	method	was	able	to	separate	WAR	and	
metabolites	enantiomers	from	each	other	[15,19].	
	
4.	Conclusions	
	
In	 summary,	 we	 have	 developed	 a	 rapid,	 accurate	 and	
robust	 LC‐MS/MS	method	 for	 simultaneous	 quantification	 of	
WAR	and	three	of	 its	main	metabolites	 in	human	plasma.	We	
used	 chiral	 chromatography	 to	 separate	 enantiomers	 of	 each	
analyte	and	have	successfully	applied	this	method	for	analysis	
of	patient	plasma	under	WAR	treatment.	
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